Sahakyan Nare, Haddad Amir, Richardson Shye, Forcha-Etieundem Valery, Christopher Lee, Alharbi Hanan, Campbell Robert
Massachusetts College of Pharmacy and Health Sciences, 19 Foster St. Worcester, MA 01608, United States.
Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences, 19 Foster St. Worcester, MA 01608, United States.
Anticancer Agents Med Chem. 2017;17(8):1033-1039. doi: 10.2174/1871520617666170102150730.
Nanotechnology has brought about the advent of personalized medicine in the era of targeted therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and summarize relevant ongoing preclinical and clinical trials.
在癌症治疗的靶向治疗策略时代，纳米技术带来了个性化医疗的出现。利用肿瘤特征实现治疗获益的能力使得制造更有效的用于癌症治疗的纳米药物成为可能。然而，包括无法克服肿瘤病理生理屏障在内的已知障碍阻碍了疾病管理。尽管如此，最近已努力开发更多采用主动靶向方法的功能化纳米系统。本文在个性化纳米医学的总体框架内综述了美国食品药品监督管理局（FDA）批准的癌症药物递送系统。我们讨论了功能化纳米系统开发方面的最新努力，并总结了相关正在进行的临床前和临床试验。
